Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Viral load news

Show

From To
Beliefs about reduced infection risk on ART linked to STI risk

People who believed that having undetectable viral load on antiretroviral therapy reduces the risk of passing on HIV were more likely to have a sexually

Published
04 March 2010
By
Keith Alcorn
Symptoms associated with increased risk of viral load rebound in patients taking HIV treatment

A high burden of physical and psychological symptoms is associated with an increased risk of viral load rebounding to detectable levels in patients taking HIV

Published
02 March 2010
By
Michael Carter
Second-line ART in South Africa shows good results

High rates of increased CD4 cell counts and viral suppression, together with low mortality were seen in adults at a large HIV public-sector urban clinic

Published
01 February 2010
By
Carole Leach-Lemens
Early treatment and interruption makes no difference to disease progression, study finds

The largest study yet done on the whether immediate antiretroviral therapy (ART) may benefit people with recent HIV infection has found that immediate treatment followed

Published
04 September 2009
By
Gus Cairns
Cheap viral load test is as reliable as standard: Botswana places large order

A new viral load test designed for resource-poor settings is as reliable as a standard assay, according to a report in the Journal of Acquired

Published
01 September 2009
By
Gus Cairns
High probability that HIV viral load remains suppressed between tests: implications for infectiousness debate

Individuals who are taking antiretroviral therapy and have had their viral load suppressed to undetectable levels can be confident that it will remain undetectable

Published
19 August 2009
By
Michael Carter
Earlier treatment could be cost-effective for South Africa

Starting treatment at a CD4 count of 350 would be cost-effective in South Africa, with a maximum extra expenditure of $1.5 billion over five years

Published
07 August 2009
By
Keith Alcorn
Abacavir as potent as tenofovir for patients starting HIV treatment with a high viral load

Regardless of baseline viral load, an HIV treatment combination that includes abacavir (Ziagen, also in the combination pill Kivexa) is just as effective at suppressing

Published
06 August 2009
By
Michael Carter
Further evidence of needless treatment switches in absence of viral load testing

Further evidence has emerged that a substantial proportion of switches to second-line treatment in a resource-limited setting, triggered in the absence of viral load testing,

Published
13 July 2009
By
Keith Alcorn
Defining, and then watching for, treatment failure

A review of various clinical, immunological and virological definitions of antiretroviral treatment failure in resource-limited settings.

Published
31 October 2007
From
HIV & AIDS treatment in practice

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.